In their letter, 1 commenting to our paper, 2 Lo Vasco et al. precise the prognostic data of the MDS patients included in their original paper 3 on cryptic deletions of the inositide-specific phospholipase c b1 gene (PI-PLC b1). All the patients with MDS and a normal karyotype at diagnosis were at high risk as evaluated by clinical meanings (French-American-British classification (FAB), International Prognostic Scoring System (IPSS)). In our series, 2 selection of the patients was done according to the unique criteria given by Lo Vasco et al. in their original paper, 3 that is, the evidence of a normal karyotype at diagnosis. The IPSS score in our cases was low (12 patients), intermediate (10) or high (1) . The discrepancies between the results of both studies probably can be explained by differences in the selection of the MDS populations. The data of Lo Vasco, 1, 3 strictly related to high-risk IPSS categories, show that, respectively, 4/9 and 4/13 cases bear the PI-PLC b1 deletion. On the contrary, in our series where only one patient was at high risk, none of the 23 patients showed a cryptic deletion of band 20p12.3.
2 Similar observations were recently done by Verburgh et al. 4 who failed to detect a deletion of the PI-PLC b1 gene in a series of 33 MDS patients with normal karyotype, of which two belonged to the high-risk group as defined by the IPSS. In the same way, no deletion was observed in the 10 low-risk MDS patients reported in the comment of Lo Vasco et al. 1 All these data indicate that the deletion of the PI-PLC b1 gene probably will not be detected in MDS patients with normal karyotype and low or intermediate IPSS risks. Conversely, in the high-risk group, the deletion could be frequent (about one-third of the reported cases till now) and associated with alterations of the signalling pathways and short survivals. 102: 670a, abstract), investigated by gene expression profiling (GEP) of B-cell chronic lymphocytic leukemia (B-CLL) cells the genes whose expression was associated with that of CD38, a well-known marker of aggressive disease course. 2 Interestingly, among the genes found as overexpressed in CD38-positive B-CLLs, they were able to identify CD49d, a.k.a. a4 integrin, a gene transcribing for a molecule functionally acting as adhesion Letters to the Editor structure for extracellular matrix components. 3 Results of GEP experiments were confirmed at the protein level by investigating the co-expression of CD38 and CD49d on B-CLL cells by flow cytometry. 1 A novel approach to analyze the simultaneous and coordinated expression of wide arrays of surface antigens by B-CLL cells has been recently proposed by us and named, in analogy with GEP, surface-antigen expression profiling. 4 According to this method, antigen expression values, as identified by flow cytometry, can be analyzed by data-mining tools identical to those employed in GEP studies, including unsupervised and supervised algorithms, with the aim of identifying the immunophenotypic signatures of specific B-CLL subsets. In particular, since we were interested in the immunophenotypic characterization of B-CLL subsets with different prognosis, we investigated the expression of a wide panel of surface markers, including cell-adhesion molecules, integrins, complement activity regulators, myeloid, T and B antigens, in a cohort of B-CLLs, all with survival data available. By sequentially applying unsupervised (hierarchical and non-hierarchical) clustering algorithms, and the nearest shrunken centroids method as class predictor, we identified three immunophenotypic profiles, one corresponding to good prognosis B-CLLs and two characterizing disease subgroups with shorter survivals. A striking finding of these studies was the correlated overexpression of both CD38 and CD49d, identified as part of the signature characterizing one of the two B-CLL subgroups with worse prognosis. Preliminary results of these studies were reported at the 2003 Meeting of the American Society of Hematology (Gattei et al., Blood 2003; 102: 667a, abstract).
C
In the present report, we propose some additional data and analyses regarding the correlation between CD38 and CD49d expression levels in B-CLL, not reported in our original study. 4 In particular, we demonstrate herein the clinical relevance of CD49d as a novel adverse prognosticator for B-CLLs, and provide evidence that a combined analysis of CD38 and CD49d expression in B-CLL can improve the predictive power of either of the two factors.
The study includes peripheral blood samples from 115 patients, all affected by typical B-CLL. The median age at diagnosis was 62 years (range 32-97) and the male to female ratio was 1.2 (76 males, 61 females). The distribution of clinical stages at diagnosis according to Rai's criteria, available for 100 out of 115 patients, was as follows: 32%, stage 0; 37%, stage I; 27%, stage II; 2%, stage III; 2%, stage IV. The IgV H mutational status, available for 96 out of 115 cases, was exactly as described. 5, 6 According to the standard cut-off of 2% deviation from the corresponding germ-line sequence, employed to discriminate between mutated (M) or unmutated (UM) IgV H gene configuration, 5, 6 M B-CLLs have significantly longer survivals, as compared to UM cases, also in our series (P ¼ 2.7 Â 10 À5 , data not shown). Expression of CD38 and CD49d was analyzed by three-color immunofluorescence, as described previously, 4 by combining phycoerythrin-conjugated anti-CD38 or anti-CD49d monoclonal antibodies (mAbs) with fluorescein isothiocyanate-and allophycocyanin-conjugated anti-CD19 and anti-CD5 mAbs. Irrelevant isotype-matched antibodies (Becton-Dickinson) were used to determine the background fluorescence. Viable, antibody-labeled B-CLL cells were identified according to CD5 or CD19 expression/side scattering, electronically gated and analyzed on a FACScalibur flow cytometer (Becton-Dickinson). Expression data were reported as the percent of CD5 þ CD19 þ B-CLL cells displaying specific fluorescence intensity greater than 98-99% of the same cell population stained with isotypeand fluorochrome-matched control immunoglobulins. In analogy to previous studies, 2 a cut-off of 30% of positive cells was chosen to discriminate between CD38 low and CD38 high or CD49d low and CD49d high B-CLLs. Figure 1a reports the relationship between CD38 and CD49d expression, as evaluated by flow cytometry, in the 115 B-CLL cases of our series. Using the cut-off value of 30% of positive cells for both the antigens, 58 out of 115 cases (50.4%) were concordantly CD38 low /CD49d low and 30 cases (26%) were concordantly CD38 high /CD49d high ( Figure 1a) . Conversely, CD38 protein in the absence of CD49d (CD38 high /CD49d low ) was documented in 10 cases (8.7%), while a CD38 low / CD49d high configuration was found in 17 out of 115 cases (14.8%). Overall, the association between the two antigens was highly significant (w 2 test, P ¼ 1.62 Â 10 À7 ). Given this striking correlation, we sought whether CD49d expression, like CD38, 2 could act as a negative prognosticator for B-CLL. As shown in Figure 1b, 
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These results suggested to investigate whether the negative prognostic impact of CD49d on B-CLL patient survivals was merely due to its correlation with the expression of CD38 or, more intriguingly, expression of the two molecules may provide complementary prognostic information on B-CLL patient survivals. Despite the relationship between CD38 and CD49d expression, 27 out of 115 cases (23.5%) were discordant regarding the expression of the two antigens. We could therefore split the whole series into four subgroups with concordant (CD38 (Table 1) .
In conclusion, in the present study, along with a correlated expression between CD38 and the integrin a-chain CD49d by B-CLL cells, we demonstrate: (i) the association between worse prognosis and overexpression of CD49d and (ii) the complementary value of CD38 and CD49d as adverse prognosticators in B-CLLs. The adverse prognostic impact of CD49d is consistent with the demonstration of higher expression levels of CD49d in B-CLL cells from advanced-stage patients, 7 as well as with the notion that engagement of a4b1 integrin, as expressed by B-CLL cells, triggers a signaling cascade eventually preventing apoptosis. 8 We propose, therefore, to introduce the flowcytometric evaluation of CD49d expression levels in the prognostic assessment of B-CLL patients.
